Advancements in platform and technology developments for bispecific and multispecific antibodies are leading to a profusion of new constructs that promise better functionality and efficacy than ever before. These efforts, combined with the careful analysis and assessment of preclinical and clinical results, will help to advance the field forward and propel novel modalities to FDA approval, and ultimately, to patients. However, additional improvements in manufacturability and safety need to be made to ensure their dominance in the marketplace. Industry leaders will be discussing translational approaches and optimisation of candidates to advance this growing repertoire of successful multispecific antibody therapeutics through clinical development to the market.

For more details on the conference, please contact:

Christina Lingham
Executive Director, Conferences and Fellow
Cambridge Healthtech Institute
Phone: (+1) 508-813-7570
Email: clingham@healthtech.com

For sponsorship information, please contact:

Companies A-K
Jason Gerardi
Sr. Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-5452
Email: jgerardi@healthtech.com

Companies L-Z
Ashley Parsons
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-1340
Email: ashleyparsons@healthtech.com

Conference Programs

• Display of Biologics
• Engineering Antibodies
• Machine Learning: Part 2

• Antibody-Based Therapies
• Emerging Targets & Approaches
• Membrane Protein Targets

• Safety & Efficacy
• Advancing Multispecifics
• Engineering Bispecifics

• Modulating the TME
• Innovative CAR T Therapy
• Next-Gen Immunotherapies

• Optimisation & Developability
• Analytical Characterisation
• Protein Stability & Formulation

• Data Science & Engineering
• Optimising Expression
• Process Development

• Intro to Machine Learning
• Machine Learning: Part 1
• Machine Learning: Part 2

• Antibody-Based Therapies
• Engineering Conjugates
• Next-Gen Immunotherapies

---